首页|蒲地蓝消炎口服液联合奥司他韦对急性上呼吸道感染患儿临床症状消失及炎症反应的影响

蒲地蓝消炎口服液联合奥司他韦对急性上呼吸道感染患儿临床症状消失及炎症反应的影响

扫码查看
目的 探讨蒲地蓝消炎口服液联合奥司他韦对急性上呼吸道感染(Upper Respiratory Tract Infection,URTI)患儿临床症状消失及炎症反应的影响.方法 随机选择2019年3月—2022年3月新泰市人民医院收治的URTI患儿360例为研究对象,根据随机数表法分为对照组和研究组,对照组180例,应用奥司他韦治疗,观察组180例,应用蒲地蓝消炎口服液联合奥司他韦治疗,连续治疗2个疗程后,比较两组临床疗效、临床症状消失及炎症反应指标、不良反应.结果 治疗后观察组临床总有效率(98.33%)高于对照组(92.22%),差异有统计学意义(χ2=7.470,P<0.05);观察组症状消失时间较对照组更短,差异有统计学意义(P<0.05).观察组的血清肿瘤坏死因子-α(Tumor Necrosis Factor-α,TNF-α)、白细胞介素-6(Interleukin-6,IL-6)、超敏C反应蛋白(High Sensitive C-creactive Protein,hs-CRP)均低于对照组,差异有统计学意义(P均<0.05);组间不良反应发生率比较,差异无统计学意义(P>0.05).结论 蒲地蓝消炎口服液联合奥司他韦治疗URTI能提升疗效,加快患儿临床症状消退,减轻炎症反应,且安全性较高.
Effect of Pudilan Xiaoyan Oral Liquid Combined with Oseltamivir on the Disappearance of Clinical Symptoms and Inflammation in Children with Acute Upper Respiratory Tract Infection
Objective To investigate the effects of Pudilan Xiaoyan oral liquid combined with oseltamivir on the disap-pearance of clinical symptoms and inflammation in children with acute upper respiratory tract infection(URTI).Meth-ods A total of 360 children with URTI treated in Xintai People's Hospital from March 2019 to March 2022 were ran-domly selected and divided into control group and observation group according to random number table method.Con-trol group one hundred and eighty cases were treated with oseltamivir,observation group one hundred and eighty cases were treated with Pudilan Xiaoyan oral liquid combined with oseltamivir.After 2 consecutive courses of treatment,the clinical efficacy,disappearance of clinical symptoms,inflammatory response indexes and adverse reactions were com-pared between the two groups.Results The total effective rate(98.33%)in the observation group was significantly higher than that(92.22%)in the control group,the difference was statistically significant(χ2=7.470,P<0.05),and the disappearance time of symptoms in the observation group was significantly shorter than that in the control group,the difference was statistically significant(P<0.05).The serum levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and high sensitive c-reactive protein(HS-CRP)in the tumor necrosis factor group were significantly lower than those in the control group,the differences were statistically significant(all P<0.05).There was no statistically signifi-cant difference in incidence adverse reactions between groups(P>0.05).Conclusion Pudilan Xiaoyan oral liquid com-bined with oseltamivir in the treatment of URTI can improve the curative effect,accelerate the regression of clinical symptoms,reduce the inflammatory response,and have high safety.

Acute upper respiratory tract infectionPudilanOseltamivirClinical symptomsInflammatory response

王建利、马柱

展开 >

新泰市人民医院儿三科,山东泰安 271200

急性上呼吸道感染 蒲地蓝 奥司他韦 临床症状 炎症反应

2024

中外医疗
卫生部医院管理研究所 二十一世纪联合创新医药科学研究院

中外医疗

影响因子:0.909
ISSN:1674-0742
年,卷(期):2024.43(1)
  • 15